Table 1.
Adverse event terminology and definitions.
Table 2.
Screening and pre-treatment (baseline) characteristics.
Fig 1.
AE–adverse event, FU–follow up, M–Month, LLM—Loa loa microfilaraemia measurement, LFU–Lost to FU, Tx–treatment.
Fig 2.
Loa loa microfilaraemia in individual participants by treatment group and geometric means of microfilaraemia by treatment group.
mf per ml: microfilaria per millilitre of blood.
Table 3.
Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.
Table 4.
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Fig 3.
Minimum, 25%, 50th, 75th percentile and maximum of the % reduction from pre-treatment values.
P placebo, 2x 2 doses albendazole, 6x 6 doses albendazole, -1 value obtained during screening (4–12 weeks prior to baseline measurement and first treatment), 2, 4, 6, 8, 10, 14, 18, 21, 24 Months after the first treatment at which LLM was measured.
Table 5.
Longitudinal trend in Loa loa microfilaraemia from baseline up to 11–12 months after completion of each regimen.
Fig 4.
M. perstans microfilariae levels in participants in whom M. perstans was detectable at least once during the study by treatment group.
mf per ml: microfilaria per millilitre of blood.